Methylergonovine Maleate has 30 known drug interactions based on U.S. FDA drug labeling data. Of these, 16 are contraindicated combinations that should be avoided entirely. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Cotrimoxazole, Delavirdine. Patients taking Methylergonovine Maleate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 30
- Contraindicated
- 16
- Major
- 5
- Moderate
- 9
Contraindicated (16)
- Methylergonovine Maleate + Clarithromycin— Macrolide antibiotic and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including…
- Methylergonovine Maleate + Cotrimoxazole— Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine to avoid vasospasm risk.
- Methylergonovine Maleate + Delavirdine— Potent CYP 3A4 inhibitor (HIV reverse transcriptase inhibitor); rare reports of serious adverse events including vasospa…
- Methylergonovine Maleate + Erythromycin— Potent CYP 3A4 inhibitor; rare reports of serious adverse events including vasospasm leading to cerebral ischemia and ex…
- Methylergonovine Maleate + Fluconazole— Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine to avoid vasospasm risk.
- Methylergonovine Maleate + Fluvoxamine— Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine to avoid vasospasm risk.
- Methylergonovine Maleate + Grapefruit Juice— Strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vasospasm leading to cer…
- Methylergonovine Maleate + Indinavir— HIV protease inhibitor and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids includi…
- Methylergonovine Maleate + Itraconazole— Azole antifungal and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vas…
- Methylergonovine Maleate + Ketoconazole— Azole antifungal and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vas…
- Methylergonovine Maleate + Nefazodone— Strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vasospasm leading to cer…
- Methylergonovine Maleate + Nelfinavir— HIV protease inhibitor and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids includi…
- Methylergonovine Maleate + Ritonavir— HIV protease inhibitor and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids includi…
- Methylergonovine Maleate + Saquinavir— Strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vasospasm leading to cer…
- Methylergonovine Maleate + Troleandomycin— Macrolide antibiotic and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including…
- Methylergonovine Maleate + Voriconazole— Azole antifungal and strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vas…
Major (5)
- Methylergonovine Maleate + Nevirapine— Strong CYP 3A4 inducer; likely to decrease the pharmacological action of methylergonovine maleate.
- Methylergonovine Maleate + Phenylephrine Hci— Ergot alkaloid that increases the pressor effect of phenylephrine hydrochloride.
- Methylergonovine Maleate + Phenylephrine Hydrochloride— Ergot alkaloid that increases the pressor effect of phenylephrine hydrochloride.
- Methylergonovine Maleate + Phenylephrine Hydrochloride Injection, Solution— Ergot alkaloid increases pressor effect of phenylephrine hydrochloride.
- Methylergonovine Maleate + Rifampin— Strong CYP 3A4 inducer; likely to decrease the pharmacological action of methylergonovine maleate.
Moderate (9)
- Methylergonovine Maleate + Chlorzoxazone— Weak CYP 3A4 inhibitor; should be administered with caution due to potential vasospasm risk.
- Methylergonovine Maleate + Cilostazol— Weak CYP 3A4 inhibitor; should be administered with caution due to potential vasospasm risk.
- Methylergonovine Maleate + Fluoxetine— Less potent CYP 3A4 inhibitor; should be administered with caution due to potential vasospastic effects.
- Methylergonovine Maleate + Halothane— Anesthetic that may reduce the oxytocic potency of methylergonovine maleate.
- Methylergonovine Maleate + Methoxyflurane— Anesthetic that may reduce the oxytocic potency of methylergonovine maleate.
- Methylergonovine Maleate + Nitroglycerin— Methylergonovine produces vasoconstriction and can reduce the effect of glyceryl trinitrate and other antianginal drugs.
- Methylergonovine Maleate + Nonselective Beta-Adrenergic Antagonists— Concomitant administration may enhance the vasoconstrictive action of ergot alkaloids; caution should be exercised.
- Methylergonovine Maleate + Ranitidine— Weak CYP 3A4 inhibitor; should be administered with caution due to potential vasospasm risk.
- Methylergonovine Maleate + Zileuton— Less potent CYP 3A4 inhibitor; should be administered with caution due to potential vasospastic effects.